Clinical Trials Browser

Glioblastoma × Fluorodeoxyglucose F18 × Clear all

NCT06815029 2025-06-26

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Phase 1 Recruiting

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT03732352 2024-11-12

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Phase 2 Completed

Glioblastoma

NCT01246869 2024-10-01

Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water

Phase 1 Terminated

Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Neoplasms

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

Glioblastoma, Gliosarcoma

NCT04315584 2020-03-24

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

Phase EARLY_PHASE1 Unknown

Glioblastoma, Recurrence

NCT01806675 2019-10-03

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Phase 1/2 Completed

25 enrolled 14 charts

BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gliosarcoma, Breast Neoplasms, Male